Pharmacology & ToxicologybioRxivPreprint
Developing selective FPR2 agonists can be a potential approach to treat moderate to severe asthma.
S. A. Visaga, H. Kalonia, V. Verma…·R. Tandon
The paper develops selective FPR2 agonists and shows they reduce non-resolving inflammation in asthma models.
DOI 10.1101/2021.09.16.460577